XRAY at a glance
DENTSPLY SIRONA Inc (XRAY, SEC CIK 818479) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 13, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), DENTSPLY SIRONA Inc (XRAY) reported revenue of $3.7 billion (down 3.0% from FY2024) and a net loss of $598.0 million. Diluted EPS was -$3.00.
- As of September 30, 2026, 37 institutional investment managers tracked by SignalX reported holding DENTSPLY SIRONA Inc (XRAY) shares worth $831.3 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by HOSEIN CLYDE on June 15, 2026 of 6,500 shares at $9.98 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $3.7B
- −3.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 37 funds
- $831.3M · +2 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Q3 net sales down 5.2% YoY; segment revenue amounts not visible in provided table
- Gross margin 52.9% vs 48.8% YoY; SG&A margin 43.4% vs 39.4%
- Wellspect best segment, sales up 4.1% constant currency; OIS worst, down 7.2%
- Operating cash flow increased, aided by $47M tariff refunds and lower receivables
- Outlook: $165M-$185M 2026 capex; macro, tariffs, inflation and distributor inventory headwinds
Risk Factors
- No material changes from the 2025 Form 10-K risk factors
- Carried-forward risks include regulatory, operational, competitive, market, and financial exposures disclosed in the 2025 Form 10-K
AI summary of the XRAY 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 fiscal 2026 results for the quarter ended September 30, 2026
- Press release Exhibit 99.1 contains the financial results and management commentary
Item EX-99.1: Item EX-99.1
- Q3 sales $836M, down 7.6% YoY, with declines across three core segments; Wellspect grew 10.1%
- Adjusted EPS $0.29, down 29.4%, and adjusted EBITDA margin 17.3% vs 18.4%, indicating weaker operating leverage
Item 2.03: Creation of a Direct Financial Obligation
- Note Purchase Agreement Amendments and Third Amendment to Credit Agreement create or modify debt obligations
- Terms, borrowing amounts, interest rates and maturities require review of Item 1.01 for financing impact
Item 1.01: Entry into a Material Definitive Agreement
- Lenders approved covenant relief through September 30 and December 31, 2026, raising permitted total and senior leverage ratios
- EBITDA addback for specified cash charges, supporting covenant compliance during fiscal 2026
Item 2.02: Results of Operations and Financial Condition
- Q2 fiscal 2026 results for quarter ended June 30, 2026
- Press release Exhibit 99.1 contains the company’s financial results
Item EX-99.1: Item EX-99.1
- Q2 sales $898M, down 4.1% reported and 6.3% constant currency, signaling continued top-line pressure
- GAAP EPS $0.18 versus $(0.22), while adjusted EPS held at $0.52 despite adjusted EBITDA declining 3.3% to $190M
AI summaries of XRAY 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for XRAY
Don't miss the next XRAY filing
- Alerts as it files. A push when XRAY files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut XRAY, by share count.
- Ask anything. An AI agent that reads every XRAY filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Czerney Kevin | F | Nov 11, 2026 | 2,273 | - |
| Barton-Brobst Lindi Rene | F | Nov 11, 2026 | 1,704 | $9.76 |
| MAZELSKY JONATHAN JAY | A | Sep 30, 2026 | 3,323.433 | $9.03 |
| Fortson John C. | A | Aug 10, 2026 | 24,014 | - |
| Fortson John C. | A | Aug 10, 2026 | 104,200 | - |
| Frohning Andrea L. | F | Aug 7, 2026 | 802 | $12.12 |
| MAZELSKY JONATHAN JAY | A | Jun 30, 2026 | 2,841.83 | $10.56 |
| HOSEIN CLYDE | Buy | Jun 15, 2026 | 6,500 | $9.98 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $3.8B | $3.7B |
| Gross Profit | - | $2.0B | $1.8B |
| Operating Income | - | -$879.0M | -$422.0M |
| Net Income | - | -$910.0M | -$598.0M |
| Gross Margin | - | 51.6% | 50.0% |
| Op. Margin | - | -23.2% | -11.5% |
| Net Margin | - | -24.0% | -16.3% |
| Balance Sheet | |||
| Total Assets | $7.4B | $5.8B | $5.4B |
| Equity | $3.3B | $1.9B | $1.3B |
| ROE | - | -46.9% | -44.7% |
| Per Share | |||
| EPS | $-0.62 | $-4.48 | $-3.00 |
| Cash Flow | |||
| Operating CF | $377.0M | $461.0M | $235.0M |
Source: XBRL data in DENTSPLY SIRONA Inc (XRAY)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate XRAY share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 37 | $831.3M |
| Q2 2026 | 35 | $983.0M |
| Q1 2026 | 33 | $839.6M |
| Q4 2025 | 31 | $898.6M |
| Q3 2025 | 32 | $1.14B |
| Q2 2025 | 32 | $1.58B |
| Q1 2025 | 29 | $936.5M |
| Q4 2024 | 27 | $951.1M |
- AQR Capital Management+1.37M (+13%)
- Goldman Sachs Group+983.8K (+53%)
- Ameriprise Financial+957.6K (+587%)
- Renaissance Technologies LLC+554.1K (+1656%)
- Citigroup+343.2K (+79%)
- BlackRock−587.8K (-2%)
- Millennium Management−451.3K (-53%)
- Citadel Advisors LLC−422.5K (-55%)
- Vanguard Portfolio Management LLC−384.2K (-3%)
- Bank of America Corp−205.5K (-7%)
- Mangrove Partners+68.4K
- Truist Financial+20.7K
- M&T Bank+11.0K
- Atlantic Union Bankshares Corp+76
- FMR LLC (Fidelity)−1.57M
- Allstate−78.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 256 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
XRAY filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 13, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 8-K | Oct 9, 2026 | - | Analysis | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 8-K | Aug 7, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | - | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 8-K | Jun 11, 2026 | - | - | - |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - |
Related Health Care companies
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ABSI · Absci CorpServices-Commercial Physical & Biological Research
- ACHC · Acadia Healthcare Company IncServices-Specialty Outpatient Facilities, NEC
XRAY SEC filings: frequently asked questions
Which institutions hold XRAY stock?
As of September 30, 2026, the largest DENTSPLY SIRONA Inc (XRAY) holders among the 13F filers tracked by SignalX were BlackRock ($231.5 million), AQR Capital Management ($104.8 million), Vanguard Portfolio Management LLC ($101.0 million), State Street Corp ($81.8 million), Vanguard Capital Management LLC ($80.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was XRAY's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), DENTSPLY SIRONA Inc (XRAY) reported revenue of $3.7 billion (down 3.0% from FY2024) and a net loss of $598.0 million. Diluted EPS was -$3.00. The figures come from the XBRL data in the 10-K.
What did XRAY report in its latest 8-K?
DENTSPLY SIRONA Inc (XRAY) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 fiscal 2026 results for the quarter ended September 30, 2026.
What are the latest XRAY SEC filings?
DENTSPLY SIRONA Inc (XRAY) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 13, 2026.
What is XRAY's SEC CIK number?
DENTSPLY SIRONA Inc (XRAY)'s SEC Central Index Key (CIK) is 818479. EDGAR lists every XRAY filing under that number.
Ask anything about XRAY
The research agent reads XRAY's filings, financials, insider trades and 13F holders, then answers with sources.